Lawrence Robbins, MD, Robbins Headache Clinic, Riverwoods, IL, discusses the efficacy and safety profile of CGRP-directed monoclonal antibody treatment in migraine. CGRP-directed antibodies have been relatively effective and comparable in terms of activity to botulinum toxin. However, the side-effect profile has become much worse than what was initially observed. Many of the predicted side effects of CGRP-directed antibody treatment have been observed in clinical practice. This will have to be addressed in the future to improve the treatment of migraine. This interview was conducted during the virtual 2021 World Congress on Controversies in Neurology (CONy) meeting.
Dr Robbins is a speaker for Amgen, Teva, Lundbeck, Biohaven and Abbvie.